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ConsanguinityCongenital disorders of glycosylation (CDG) are caused by a dysfunction of glycosylation, an essential step in
the manufacturing process of glycoproteins. This paper focuses on a 6-year-old patient with a new type of
CDG-I caused by a defect of the steroid 5α reductase type 3 gene (SRD5A3). The clinical features were psy-
chomotor retardation, pathological nystagmus, slight muscular hypotonia and microcephaly. SRD5A3 was re-
cently identiﬁed encoding the polyprenol reductase, an enzyme catalyzing the ﬁnal step of the biosynthesis
of dolichol, which is required for the assembly of the glycans needed for N-glycosylation.
Although an early homozygous stop-codon (c.57G>A [W19X]) with no functional protein was found in the
patient, about 70% of transferrin (Tf) was correctly glycosylated. Quantiﬁcation of dolichol and unreduced
polyprenol in the patient's ﬁbroblasts demonstrated a high polyprenol/dolichol ratio with normal amounts
of dolichol, indicating that high polyprenol levels might compete with dolichol for the initiation of
N-glycan assembly but without supporting normal glycosylation and that there must be an alternative
pathway for dolichol biosynthesis.
© 2011 Elsevier Inc. All rights reserved.1. Introduction
1.1. CDG
Congenital disorders of glycosylation (CDG) are severe diseases
with multiple systemic features that often remain undiagnosed.
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t al., Life with too much polymanufacturing called glycosylation, which is localized in the endo-
plasmatic reticulum (ER) and the Golgi compartment.
In the ﬁrst biosynthetic step of the glycan moiety used for
N-glycosylation, several monosaccharides are assembled on dolichyl
phosphate, a lipid anchor in the ER membrane, generating a lipid-
linked oligosaccharide (LLO) consisting of 14 saccharide units (Glc3-
Man9GlcNAc2). Four Man and all Glc residues are transferred to the
growing LLO structure from dolichol-phosphate-mannose (Dol-P-
Man) or Dol-P-Glc intermediates, respectively. The oligosaccharyl
transferase (OST) subsequently transfers this structure en bloc to an
asparagine within a so-called glycosylation consensus sequence of a
nascent protein. Afterwards, the N-linked glycan is trimmed and
elongated in a series of reactions ending in the late Golgi
compartment.
Depending on where the process of glycosylation is disrupted, the
corresponding disorders were called CDG-I or -II. CDG-I involved all
defects concerning the biosynthetic reactions up to and including
OST, whereas CDG-II disorders were localized within the subsequent
modiﬁcations of the protein-linked oligosaccharide [1]. A new no-
menclature was recently proposed [2,3]. It includes defects of protein
N-glycosylation and O-glycosylation, defects of glycosphingolipid and
glycosylphosphatidylinositol anchor glycosylation, and defects in
multiple glycosylation and other pathways, including SRD5A3-CDG.prenol: polyprenol reductase deﬁciency, Mol. Genet. Metab. (2012),
2 J.E.H. Gründahl et al. / Molecular Genetics and Metabolism xxx (2012) xxx–xxxMajor features of CDG syndrome include psychomotor retarda-
tion, cardiomyopathy, decreased antithrombin III activity, abnormal
eye movements or failure to thrive [4,5].1.2. Dolichol phosphate biosynthesis and SRD5A3
Dolichol belongs to the family of long-chain polyisoprenoids with
one terminal saturated isoprene unit. It was discovered and extracted
from pig liver and human kidney in 1960 [6]. Seven years later,
Behrens and Leloir [7] described dolichol phosphate as a membrane
bound polyisoprenyl lipid-anchor needed for N-glycosylation. Its bio-
synthetic pathway was proposed, though incomplete by reason of
several unknown enzymes [8].
The ﬁrst part of dolichol biosynthesis in mammals is the mevalo-
nate pathway. Two acetyl-CoA molecules condense to acetoacetyl-
CoA with the release of CoA-SH. 3-hydroxy-3-methyl-glutaryl-CoA
(HMG-CoA) synthase adds another acetyl-CoA creating HMG-CoA
which is reduced to mevalonate by HMG-CoA reductase.
During the second phase, several ATP-depending phosphorylation
reactions, a decarboxylation and a ﬁnal dephosphorylation step result
in isopentenyl diphosphate. Isopentenyl diphosphate and its isomere,
dimethylallyl diphosphate, react to form geranyl diphosphate releas-
ing a diphosphate. A following prenyltransferase catalyzes in a similar
way the condensation of geranyl diphosphate with isopentenyl di-
phosphate creating farnesyl diphosphate. Farnesyl diphosphate is
the basic intermediate for the biosynthesis of cholesterol, ubiquinone
and dolichol.
The unique part of dolichol biosynthesis starts with a speciﬁc cis-
prenyltransferase which successively adds isopentenyl diphosphate
units to generate dehydrodolichol diphosphate (syn. polyprenyl
diphosphate). In the current model, a polyprenyl diphosphate phos-
phatase removes both phosphate residues generating polyprenol
(dehydrodolichol), although this phosphatase still needs to be
veriﬁed [9,10]. At this point, polyprenol reductase reduces the
polyprenol's alpha isoprene unit using nicotinamide adenine dinucle-
otide phosphate (NADPH) and generating dolichol [8,11] (Fig. 1).Fig. 1. Last steps of the current dolichol-P biosynthesis pathway model. Steroid 5α reductase
unit of the polyprenol creating dolichol.
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phosphate (CTP) to dolichol [11,12].
2. Methods
2.1. Isoelectric focusing (IEF) and high performance liquid
chromatography (HPLC)
For agarose-gel preparation, 22 mg agarose and 2.2 ml water were
cooked for 20–30 min before 110 μl ampholine (pH5.0–7.0; Amer-
sham Biosciences) was added. The gel was ﬁxed on Gel Fix for agarose
(Pharmacia Biotech).
The volume of 10 μl serum, 66.6 μl 0.9% NaCl and 2.3 μl 10 mM Fe-
(III)-citrat (0.0245 g/10 ml water) was incubated for 10 min at room
temperature and completed with 2.3 μl 0.1 M NaHCO3 (0.084 g/
10 ml water). The IEF ran on a Pharmacia Phast System.
Afterwards 80 μl Tf antibody (Dako A0061) was added for visuali-
zation, washed with water, stained with Coomassie blue R250 and
discolored with 300 ml Destain (350 ml ethanol+650 ml water+
100 ml acetic acid).
HPLC of carbohydrate deﬁcient Tf (CDT) was done as described
[13].
2.2. Immunoprecipitation (IMPP) and sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-Page)
IMPP and SDS-Page was done as described [14].
2.3. LLO analysis
LLO analysis was done as described [15].
2.4. Homozygosity mapping by SNP-array
The patient's genomic DNA was isolated from peripheral blood
lymphocytes by the salting out procedure as described previously
[16]. DNA was prepared and hybridized to an Affymetrix Genome-type 3 (SRD5A3) acts as polyprenol reductase by reducing the terminal alpha isoprene
prenol: polyprenol reductase deﬁciency, Mol. Genet. Metab. (2012),
Fig. 2. Family tree. The patient's parents are cousins once removed. Only one child is
affected. Digits represent the amount of people (male or female).
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ing to the manufacturer's protocol and further analyzed with an Affy-
metrix GeneChip Scanner 3000 7 G. Bioinformatic data processing
was performed using the Affymetrix Genotyping Console 4.0 with de-
fault settings. The call rate exceeded 97%. Analysis regarding regions
of homozygosity in the index patient was carried out with the Chro-
mosome Analysis Suite 1.1 Software (Annotation Files Version
NA30). Chromosomal segments were regarded as homozygous if
they contained at least10 homozygous SNPs in series, minimum seg-
ment size was set as 1 Mb.
2.5. Cell culture
Fibroblasts were cultured in MEM (Minimal Essential Medium;
PAA Laboratories (Company)-GE Healthcare) with 2 mM L-glutamine,
100 μg/ml penicillin and streptomycin, and 10% FBS (Fetal Bovine
Serum; Invitrogen). For dolichol- and polyprenol-analysis, cells
were incubated for 20 h in FBS-free MEM supplement. Afterwards
ﬁbroblasts were washed with Dulbecco's Phosphate Buffered Saline
(PAA Laboratories), trypsinized with trypsin/EDTA solution (Bio-
chrom AG), pelleted and stored at −80 °C.
2.6. Mutation analysis of SRD5A3
According to the manufacturer's protocol, RNA-preparation from
patient's ﬁbroblasts was done using the “RNeasy” Mini Kit (QIAGEN)
followed by cDNA-synthesis with SuperScript™ III Reverse Transcrip-
tase (Invitrogen/Life technologies Corp.).
With QIAmp DNA mini kit (QIAGEN) genomic DNA was isolated
from the patient's EDTA blood sample after the manufacturer's
protocol.
For ampliﬁcation the following primers synthesized by Invitrogen
were used: SRD5A3 IF(13U): (5′ to 3′) TGT AAA ACG ACG GCC AGT
AGG CTG AGA CCG GTG CGC CG; SRD5A3 IR(13R): (5′ to 3′) CAG
GAA ACA GCT ATG ACC GCC ATC CAT TGG CAC TTG GC; SRD5A3 IIF
(13U): (5′ to 3′) TGT AAA ACG ACG GCC AGT CCT GCT TTG GTG CCT
TAC TC; SRD5A3 IIR(13R): (5′ to 3′) CAG GAA ACA GCT ATG ACC
ACT GCC ATG CTC ATT CAG TG.
Q-solution was added to the master-mix before PCR cycling was
performed using the following conditions: 94 °C for 4 min; 35 cycles
(94 °C for 1 min; 68 °C for 1.5 min; 72 °C for 1.5 min); 72 °C for
10 min.
Afterwards PCR-products were treated with the USB PCR Product
Pre-Sequencing Kit from Affymetrix/USB and with the BigDye Termi-
nator Kit 3.1 (Applied Biosystems) under the terms of the manufac-
turer's protocol. Cycling conditions were: 96 °C for 2 min and 25×
(94 °C for 10 s, 50 °C for 5 s, 60 °C for 2 min). Puriﬁcation was per-
formed with Sephadex/Millipore System (Pharmacia; Millipore; Ap-
plied Biosystems) and sequencing was done on an ABI Prism 3730.
The genomic DNA was ampliﬁed with primer SRD5A3 IF(13U): (5′
to 3′) TGT AAA ACG ACG GCC AGT AGG CTG AGA CCG GTG CGC CG;
and primer SRD5A3 ex1R2(13R): (5′to 3′) CAG GAA ACA GCT ATG
ACC CTC GGC GTC CGC GGA CAC C. PCR-Conditions with Q-solution:
94 °C for 4 min; 35 cycles (94 °C for 1 min; 65 °C for 1.5 min; 72 °C
for 1.5 min); 72 °C for 5 min.
Sequencing was done as described earlier.
2.7. Lipid extraction and liquid chromatography-coupled multiple
reaction monitoring (LC-MRM) analysis of polyprenol and dolichol
in human ﬁbroblasts
Lipid extraction was performed according to Bligh and Dyer [17].
Analysis of dolichol and polyprenol in ﬁbroblast cells were performed
by LC-MRM using a Shimadzu LC system (comprising a solvent
degasser, two LC-10A pumps and a SCL-10A system controller)
coupled to a 4000 Q-Trap hybrid triple quadrupole linear ion-trapPlease cite this article as: J.E.H. Gründahl, et al., Life with too much poly
doi:10.1016/j.ymgme.2011.12.017mass spectrometer equipped with a Turbo V ion source (Applied
Biosystems Inc, Foster City, CA). LC was operated at a ﬂow rate of
200 μl/min with a linear gradient as follows: 100% of mobile phase A
was held isocratically for 2 min and then linearly increased to 100%mo-
bile phase B over 14 min and held at 100% B for 4 min. Mobile phase A
consisted of methanol/acetonitrile/aqueous 1 mM ammonium acetate
(60/20/20, v/v/v). Mobile phase B consisted of 100% ethanol containing
1 mM ammonium acetate. A Zorbax SB-C8 reversed-phase column
(5 μm, 2.1×50 mm) was obtained from Agilent.
MRM was performed in the negative ion mode with mass spec-
trometry (MS) settings as follows: CUR=20 psi, GS1=20 psi,
GS2=30 psi, IS=−4500 V, TEM=350 °C, ihe=ON, DP=−40 V,
EP=−10 V and CXP=−5 V. The voltage used for collision-induced
dissociation was −40 V. The MRM pairs are as follows: 1302.2/59
for polyprenol-18; 1370.2/59 for polyprenol-19; 1438.2/59 for
polyprenol-20; 1304.2/59 for dolichol-18; 1372.2/59 for dolichol-19;
1440.2/59 for dolichol-20. In these MRM pairs, the precursor ions
are the [M+acetate]− adduct ions, and the product ions are the ace-
tate ions (m/z 59).
3. Results
3.1. Case report
The patient is a Pakistani boy whose parents are cousins once re-
moved and with further consanguinity in the paternal line (Fig. 2).
The two other siblings are unaffected. He was born premature after
35 weeks of gestation. A neuropediatric examination at the age of
4 months revealed opisthotonus, muscle hypertonia, psychomotor re-
tardation, downbeat-nystagmus and failure of ﬁxation.
No cerebral seizures occurred, but psychomotor development was
delayed. The boy started to walk at 22 months.
At the age of 3 years, the boy was in a good general state of health.
His speech development was retarded and limited to a few single
words (mom, dad). He was attentious, cooperative, showed normal
reﬂex responses with a slight hypotonic muscle tone. His height
was 97 cm (10–15th percentile) and his head circumference 49 cm
(3–10th percentile). Blood pressure and heart rate were normal.
Laboratory examinations showed normal thyroid function (TSH,
fT3, fT4), normal lactate concentration (1.5 mmol/l) as well as refer-
ence values for LDH, transaminases, CK, CKMB, bilirubin, gamma-GT
and AP. Carbohydrate-deﬁcient Tf was increased to 16.7% (diasialo-
Tf) in 2008, indicating a congenital disorder of glycosylation. To ex-
clude a virus-induced hepatitis, the serum was checked for HAV,
HBV and HCV—all with negative results.prenol: polyprenol reductase deﬁciency, Mol. Genet. Metab. (2012),
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Cranial MRI at the age of 3 9/12 years showed no pathological
ﬁndings.
3.2. CDG diagnostics: IEF, IMPP, SDS-Page, HPLC
The standard CDG diagnostic screening is the IEF of serum Tf [18],
a protein from the liver consisting of 679 amino acids with two bi-
antennary oligosaccharides each with two negative sialic acid resi-
dues. Hypoglycosylation of this protein leads to missing saccharide-
units or missing branches and, due to the loss of sialic acids with
their electric charge, to a different isoelectric point. The major fraction
in physiologic Tf is tetrasialo-Tf.
For detailed analyses of the patient's serum we started an IEF, an
IMPP and a SDS-PAGE, separating the Tf by charge and molecular
size. These tests showed an absence of a whole glycan chain on the
protein, leading to the assumption of an early disruption of glycosyl-
ation pathway. In case of CDG-I, en bloc transfer of the glycan moiety
is reduced, leading to some Tf-molecules with only one or not any bi-
antennary glycan moiety. Thus, tetrasialo-Tf is reduced whereas di-
and asialo-Tf are increased. The results clearly identiﬁed our patient
as CDG type I (Figs. 3 and 4). A HPLC analysis in 2009 conﬁrmed
this report: 0.25% asialo-Tf, monosialo-Tf was below level of detec-
tion, 18.89% disialo-Tf, 3.44% trisialo-Tf, 73.90% tetrasialo-Tf and
3.53% pentasialo-Tf. The physiological reference values are: asialo-Tf
and monosialo-Tf: below level of detection, disialo-Tf: 1.10+/
−0.72, trisialo-Tf: 3.76+/−2.60, tetrasialo-Tf: 89.84+/−4.16,
pentasialo-Tf: 6.4+/−3.80.
3.3. LLO analysis
Analysis of LLO derived from ﬁbroblasts by HPLC gave variable re-
sults. Whereas the normal Glc3Man9GlcNAc2 peak was found in some
experiments, an accumulation of Man5GlcNAc2 was found in others,
indicating that the amount of Dol-P-Glc might be limiting.
3.4. Homozygosity mapping and DNA sequencing
Since the parents were related, homozygosity mapping was used
under the assumption of an autosomal recessive inheritance in
order to determine candidate genes involved in glycosylation present
in the homozygous genomic regions of the patient. Autosomal homo-
zygous regions over 5 Mbp were: Chromosome 3 (p21.31–p21.1;
5211 kbp), chromosome 4 (p14–p12; 10654 kbp), (q11- q21.23;
32735 kbp) and chromosome 19 (p13.12- p12; 8136 kbp).
Two genes involved in early N-glycan assembly steps were identi-
ﬁed in the homozygous regions. The gene for GDP-mannose
pyrophosphorylase B was found in the homozygous region onFig. 3. Isoelectric focusing of serum transferrin. The control shows two bi-antennary ol-
igosaccharides each with two negative sialic acid residues; the major fraction is
tetrasialo-Tf. Additional bands are seen in CDGs due to missing monosaccharide units
and missing branches. In the patient, tetrasialo-Tf is reduced whereas di- and asialo-
Tf are increased. CHO = carbohydrate side chains.
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on chromosome 4 (Fig. 5) (q11–q21.23) 196 genes were present
(based on Ensembl Genomic Browser). Among these we found the
steroid 5α reductase type 3 (SRD5A3, OMIM ID: 612379), a gene
with 318 amino acids, which was recently described [19]. Sequencing
the ampliﬁed cDNA we found a homozygous mutation in exon 1
(c.57G>A) generating a stop codon with a protein truncation after
19 amino acids (Fig. 6) suggesting a complete loss of function of
SRD5A3. The controls showed no mutation. Genomic DNA of the pa-
tient and his parents were sequenced for conﬁrmation. The parents
were heterozygous and the patient was homozygous for the
SRD5A3-mutation (c.57G>A; A/A) (Fig. 7).
3.5. LC-MRM analysis of polyprenol and dolichol in human ﬁbroblasts
Since clearly more than 70% of patient's Tf was normally glycosy-
lated, we analyzed his ﬁbroblasts and the ﬁbroblasts of two healthy
controls with LC-MRM, wondering whether N-glycan assembly in
this case occurred on polyprenol or whether there is an alternative
pathway for the biosynthesis of dolichol.
Residual amounts of polyprenols were detectable, but levels of
polyprenols in the patient were much higher than in the healthy con-
trols (Figs. 8 a and b).
Surprisingly, dolichol levels in the patient's ﬁbroblasts were com-
parable to the healthy controls (Figs. 9 a and b) leading to about 3-
folds higher polyprenol/dolichol ratios in the patient in comparison
to controls (Fig. 10).
MS data were not normalized to an internal or exogenous stan-
dard. Figures show the raw MS ion signal data.
These results suggest an alternative pathway for dolichol biosynthesis.
4. Discussion
The stepwise assembly of N-linked glycans requires dolichol, a
polyisoprenoid. In the last step of dolichol biosynthesis, the terminal
alpha isoprene unit of the polyprenol is reduced.
SRD5A3 was initially presumed to be a 5α-steroid reductase. It
was identiﬁed by a genome-wide expression proﬁle analysis in
human prostate cancer cells [20]. It consists of 318 amino acids. Re-
cent studies ideniﬁed SRD5A3 as the polyprenol reductase involved
in the ﬁnal step of dolichol biosynthesis [19].
The clinical features of SRD5A3 deﬁciency were ﬁrst described in a
consanguineous Emirati family with four affected children [21]. The
children had dysmorphic features, coloboma of the iris, retina or
optic disc, short stature, feeding difﬁculties, hypertrichosis and hy-
perkeratosis of the skin. Brain MRI revealed frontal polymicrogyria.
One of the children had a transposition of the great arteries. Five
out of seven patients had cerebellar vermis hypoplasia [19].
Genome-wide linkage analysis revealed a homozygous region on
chromosome 4 and the SRD5A3 gene was identiﬁed by mutation
analysis of candidate genes within this region [19]. Since abnormal
Tf glycosylation was found in these children, CDG-Ix patients were
screened for SRD5A3 mutations revealing a total of 11 patients with
mutations in this gene [19]. Nystagmus was reported in nearly all of
them.
Morava et al. reported 12 patients from nine families with
SRD5A3-CDG [22]. Two of the affected children were from two differ-
ent consanguineous Turkish families and were originally reported by
Prietsch [23] and Assman [24]. They had the samemutation as our pa-
tient (c.57G>A [W19X]) and showed a similar picture of clinical
symptoms: Muscle hypertonia, psychomotor retardation and nystag-
mus. By reason of the geographic distance a potential founder effect
between the two Turkish children and our patient is unlikely. Morava
et al. also compared the clinical symptoms and biochemical ﬁndings
of these 12 SRD5A3-CDG-patients and found no genotype–phenotype
correlation [22].prenol: polyprenol reductase deﬁciency, Mol. Genet. Metab. (2012),
Fig. 4. IMPP and SDS-Page. The SDS-Page separates the Tf by molecular size. Thus, hypoglycosylated Tf migrates faster, as it is shown in patient and positive control. Tetrasialo-Tf is
reduced whereas di- and asialo-Tf are increased. CHO = carbohydrate side chains.
5J.E.H. Gründahl et al. / Molecular Genetics and Metabolism xxx (2012) xxx–xxxSRD5A3 deﬁciency was also identiﬁed as the cause of Kahrizi syn-
drome [25,26]. The syndrome was described in three adult Iranian
siblings with severe mental retardation. The patients were unable to
speak. Two of the three patients had iris coloboma. The patients had
short stature, cataracts, kyphosis and joint contractures developed
later in life. No seizures occurred. Homozygosity mapping revealed
a single interval of homozygosity that was unique to the patients
and was localized to the pericentrometric region of chromosome 4.
SRD5A3 is the human ortholog of the yeast DFG10 gene. The phe-
notype of the yeast DFG10 mutant can be rescued by human SRD5A3
[19]. Disruption of the SRD5A3 gene in mice is lethal at embryonic
day 12.5 [19].Fig. 5. Copy number neutral 32, 7 Mb LOH region on
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doi:10.1016/j.ymgme.2011.12.017In SRD5A3 ﬁbroblasts we found dolichol concentrations that were
comparable to healthy controls suggesting that there must be an al-
ternative pathway for dolichol biosynthesis. In addition, polyprenol
could serve as the acceptor molecule for the biosynthesis of
N-glycans working with the lower efﬁciency.
Although the amount of dolichol was not reduced in SRD5A3 ﬁ-
broblasts, hypoglycosylation occurred in the patient. Several explana-
tions seem possible:
1.) Accumulation of intermediate products of the dolichol pathway
might be toxic and inhibit glycosylation reactions. A change of
isoprenoid levels could inﬂuence the cell's metabolism as it haschromosome 4 detected by SNP array analysis.
prenol: polyprenol reductase deﬁciency, Mol. Genet. Metab. (2012),
Fig. 6. Mutation analysis—cDNA. SRD5A3 mutation c.57G>A [W19X] in patient's cDNA.
6 J.E.H. Gründahl et al. / Molecular Genetics and Metabolism xxx (2012) xxx–xxxbeen associated with Alzheimer's disease [27–30] and neuronal
ceroid lipofuscinosis [31]. Recently a mutation in DHDDS (OMIM
ID: 613861), encoding dehydrodolichol diphosphate synthase,
was discovered in an ethnic group called Ashkenazi Jews [32].
DHDDS (syn. cis-prenyltransferase) is located two steps earlier
in dolichol de novo biosynthesis than the polyprenol reductase,
creating polyprenol by cis-prenyl elongation of farnesyl pyro-
phosphate (FPP) [32]. Interestingly, symptoms were not as severeFig. 7. Mutation analysis—gDNA. Heterozygousity for SRD5A3 (Exon 1 c.57G/A) is show
c.57G>A; A/A homozygosity). Wildtype-control: Exon 1 c.57G>A; G/G.
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doi:10.1016/j.ymgme.2011.12.017as in our patient and restricted to retinitis pigmentosa. No other
organs were affected. Referring to toxic accumulation, FPP might
have a less fatal impact than polyprenol.
2.) The 3-fold increase of polyprenol found in SRD5A3 ﬁbroblasts
could compete with dolichol as the lipid-anchor for N-
glycosylation. In the ﬁrst step of N-glycosylation, dolichol kinase
transfers phosphate from CTP to dolichol (Fig. 1) [11,12]. Sub-
strate speciﬁcity of dolichol kinase was tested in rat liver andn in the parent's gDNA. The patient's gDNA contains the SRD5A3-mutation (Exon 1
prenol: polyprenol reductase deﬁciency, Mol. Genet. Metab. (2012),
Fig. 8. a. Polyprenol in ﬁbroblasts. Analysis of polyprenol in ﬁbroblasts cells was performed by liquid chromatography-coupled multiple reaction monitoring (LC-MRM). b. Polypre-
nol in ﬁbroblasts. The results showed a higher level of polyprenols in the patient than in the healthy controls.
7J.E.H. Gründahl et al. / Molecular Genetics and Metabolism xxx (2012) xxx–xxxdemonstrated a preference for the saturation of the alpha unit
with 2.5-fold more activity concerning dolichol-16 and -19 com-
pared to the corresponding polyprenols [33]. Furthermore, for
the transfer of mannosyl residues from GDP-mannose in rats,
polyprenol was identiﬁed as a weak acceptor while dolicholPlease cite this article as: J.E.H. Gründahl, et al., Life with too much poly
doi:10.1016/j.ymgme.2011.12.017showed good results [34]. In contrast to bacteria, glycosylation
with polyprenol in human seems to be reduced if not impossible.
Nevertheless, polyprenol might compete with dolichol in early
N-glycan biosynthesis reactions thereby reducing the amount of
dolichol-linked oligsaccharides used for protein glycosylation.prenol: polyprenol reductase deﬁciency, Mol. Genet. Metab. (2012),
Fig. 9. a. Dolichol in ﬁbroblasts. Analysis of dolichol in ﬁbroblast cells were also performed by liquid chromatography-coupled multiple reaction monitoring (LC-MRM).b: Dolichol in
ﬁbroblasts. Dolichol content in the patient's ﬁbroblasts was comparable to the healthy controls.
8 J.E.H. Gründahl et al. / Molecular Genetics and Metabolism xxx (2012) xxx–xxx3.) The operating alternative pathway cannot create the necessary
amount of dolichol at the right location. One dolichol phosphate
is required as the carrier while seven others import glucose and
mannose into the ER [4]. Therefore, a locally decreased poolPlease cite this article as: J.E.H. Gründahl, et al., Life with too much poly
doi:10.1016/j.ymgme.2011.12.017of dolichol can lead to reduced glycosylation. A dolichol-
pyrophosphate-phosphatase in yeast (CWH8) and mammalian
cells (DolPP1) is known to recycle Dol-P-P after OST has trans-
ferred Glc3Man9GlcNAc2 to the protein, keeping up a steadyprenol: polyprenol reductase deﬁciency, Mol. Genet. Metab. (2012),
Fig. 10. Polyprenol/dolichol ratios in ﬁbroblasts. Due to increased levels of polyprenol, the patient's polyprenol/dolichol ratio is about 3-folds higher than in healthy ﬁbroblasts.
9J.E.H. Gründahl et al. / Molecular Genetics and Metabolism xxx (2012) xxx–xxxpool of dolichol for glycosylation [35]. Whether this is enough in
patients with SRD5A3-mutations or whether this dolichol is at
the right location still needs to be veriﬁed.
4.) The amount of dolichol-linked oligosaccharides might be sufﬁ-
cient for glycosylation in SRD5A3 ﬁbroblasts but might be insufﬁ-
cient in cells with higher rates of N-glycan biosynthesis like liver
cells.
It is intriguing to speculate that improvement of the dolichol/poly-
prenol ratio could be the key for a successful therapy for SRD5A3-
deﬁcient patients. Very little is known about the dolichol contents
of food. Polyprenols are the dominant polyisoprenoids in plant photo-
synthetic tissues accompanied by the traces of dolichols. Only plant
roots, yeast or the animal tissues could be considered as a possible
source of dolichols [36]. However, the dolichol-amount absorbed by
nutrition is known to be insigniﬁcant in rats [37]. Further research
on dolichol content in plants or food and its absorption in human
will be necessary.
Pharmacological interventions might also be possible. In CDG ﬁ-
broblasts with a dolichol-phosphate-mannose synthase deﬁciency
(CDG-Ie) the amount of dolichol-phosphate-mannose was increased
by using the squalene synthase inhibitor zaragosic acid A (ZGA) [38].
In contrast to statins, squalene synthase inhibitors inhibit choles-
terol biosynthesis later-on in the pathway, i.e. after the step where
dolichol biosynthesis is separated from the cholesterol biosynthesis
pathway. In SRD5A3, directing the metabolic ﬂux towards polyisopre-
noid biosynthesis might have contrary effects and might worsen the
patient's symptoms, e.g. if hypothesis #2 is correct. Alternatively it
might be useful if e.g. hypothesis #4 is correct.
On the other hand, statins inhibit the cholesterol and dolichol bio-
synthesis by interfering with mevalonate biosynthesis at the level of
HMG-CoA reductase and are used for treatment of patients at risk
for secondary cardiovascular events [39]. The mevalonate pathway
is the early common part of the dolichol and cholesterol biosynthesis.
Its interruption would therefore reduce not only cholesterol but poly-
isoprenoids as well. If accumulation of polyprenol was deleterious as
discussed, this might improve the patient's symptoms. Otherwise,
hypoglycosylation of proteins might increase due to reduced dolichol
production [40].
Statins have been used in Smith–Lemli–Opitz syndrome (SLOS) treat-
ment. SLOS is caused by a defect of sterol-Δ7-reductase that leads to an
accumulation of the cholesterol precursor 7-dehydrocholesterol [41]. ItsPlease cite this article as: J.E.H. Gründahl, et al., Life with too much poly
doi:10.1016/j.ymgme.2011.12.017production can be inhibited by statin treatment [42]. Pappu, Connor et
al. [43] described a 7-fold higher urinary excretion rate of dolichol and
ubiquinone in SLOS children than in control children. This again shows
a shift in the mevalonate/cholesterol pathway towards other products
such as nonsterol isoprenoids. Furthermore Pappu, Connor et al. used a
high-cholesterol diet, decreasing the urinary excretion rate of dolichol
by 70% and ubiquinone by 67%, possibly due to a negative feedback
mechanism. In patients with polyprenol reductase deﬁciency a cholester-
ol supplementation might have similar effects on the polyprenol excre-
tion and possibly on the polyprenol content in cells.
Metazoans protect themselves from potential toxic substrate ac-
cumulation in cells with a mechanism called translation attenuation.
High ER stress rates, for example due to improperly glycosylated pro-
teins, induce the protein kinase R-like ER kinase (PERK). This kinase
then phosphorylates the eukaryotic initiation factor 2α (eIEF2α),
which reduces the number of translated proteins in the ER. Hence,
fewer proteins are glycosylated but regularly [44]. Translation balan-
cing still needs to be veriﬁed in human cells. Effects on ﬁbroblasts
from CDG-Ia patients showed variable results [44] but hold promise
for a future therapeutic option.5. Conclusion
This study emphasizes the possibility of an alternative dolichol
pathway, demonstrated by normal dolichol levels in the described pa-
tient. In addition, the cell biological basis for SRD5A3-CDG pathology
is discussed and potential treatment options are demonstrated. Fur-
ther research on the alternative dolichol pathway and, along with
that, on therapeutic options for SRD5A3-CDG and other CDG is
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